Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.
2.

Encapsulated mesalamine granules (Apriso) for ulcerative colitis.

[No authors listed]

Med Lett Drugs Ther. 2009 May 18;51(1312):38-9. Review.

PMID:
19448588
3.

Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.

Abinusawa A, Tenjarla S.

Adv Ther. 2015 May;32(5):477-84. doi: 10.1007/s12325-015-0206-4. Epub 2015 May 8.

4.

Multiparticulate systems containing 5-aminosalicylic acid for the treatment of inflammatory bowel disease.

Bautzová T, Rabišková M, Lamprecht A.

Drug Dev Ind Pharm. 2011 Sep;37(9):1100-9. doi: 10.3109/03639045.2011.560156. Epub 2011 Mar 21. Review.

PMID:
21417610
5.

Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?

Sandborn WJ.

J Clin Gastroenterol. 2008 Apr;42(4):338-44. doi: 10.1097/MCG.0b013e3181595b56. Review.

PMID:
18277908
6.

MMX mesalamine.

Baker DE.

Rev Gastroenterol Disord. 2006 Summer;6(3):146-52. Review. Erratum in: Rev Gastroenterol Disord. 2006 Fall;6(4):249.

PMID:
16957657
7.

Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.

Stobaugh DJ, Deepak P, Thorpe M, Hannon B, Ehrenpreis ED.

Inflamm Bowel Dis. 2013 Feb;19(2):301-8. doi: 10.1002/ibd.23003.

PMID:
22644716
8.

In vitro biorelevant models for evaluating modified release mesalamine products to forecast the effect of formulation and meal intake on drug release.

Andreas CJ, Chen YC, Markopoulos C, Reppas C, Dressman J.

Eur J Pharm Biopharm. 2015 Nov;97(Pt A):39-50. doi: 10.1016/j.ejpb.2015.09.002. Epub 2015 Sep 21.

PMID:
26391972
9.
10.

The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid).

Klotz U.

Arzneimittelforschung. 2012 Feb;62(2):53-8. doi: 10.1055/s-0031-1299685. Epub 2012 Feb 16. Review.

PMID:
22344548
11.

[Chronic inflammatory bowel diseases. Update on evidence-based therapy].

[No authors listed]

MMW Fortschr Med. 2005 Apr 28;147(17):58-9. German. No abstract available.

PMID:
15903063
13.

Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis.

Sandborn WJ.

Am J Gastroenterol. 2002 Dec;97(12):2939-41. Review. No abstract available.

PMID:
12492172
14.
15.

Development of a novel tablet-in-capsule formulation of mesalamine for inflammatory bowel disease.

Patel MM, Amin AF.

Pharm Dev Technol. 2013 Mar-Apr;18(2):390-400. doi: 10.3109/10837450.2011.653819. Epub 2012 Feb 5.

PMID:
22304735
16.

Persistence to oral 5-aminosalicylate therapy for inflammatory bowel disease in Australia.

Selinger CP, Kemp A, Leong RW.

Expert Rev Gastroenterol Hepatol. 2014 Mar;8(3):329-34. doi: 10.1586/17474124.2014.882768. Epub 2014 Feb 4.

PMID:
24490626
17.

Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract.

Yu A, Baker JR, Fioritto AF, Wang Y, Luo R, Li S, Wen B, Bly M, Tsume Y, Koenigsknecht MJ, Zhang X, Lionberger R, Amidon GL, Hasler WL, Sun D.

Mol Pharm. 2017 Feb 6;14(2):345-358. doi: 10.1021/acs.molpharmaceut.6b00641. Epub 2016 Dec 23.

PMID:
28009518
18.

Design of a potential colonic drug delivery system of mesalamine.

Gohel MC, Parikh RK, Nagori SA, Dabhi MR.

Pharm Dev Technol. 2008;13(5):447-56. doi: 10.1080/10837450802088679 .

PMID:
18798122
19.
20.

New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut.

Fiorino G, Fries W, De La Rue SA, Malesci AC, Repici A, Danese S.

Curr Med Chem. 2010;17(17):1851-7. Review.

PMID:
20353384

Supplemental Content

Support Center